Latest On Aerie Pharmaceuticals, Inc (AERI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-11-16 07:16 EST | News | Aerie Pharmaceuticals last day of trading expected Nov. 18 as part of Alcon merger | N/A |  |
| 2022-11-03 22:31 EST | News | Aerie Pharmaceuticals Non-GAAP EPS of -$0.27 beats by $0.16, revenue of $36.1M beats by $0.8M | N/A | |
| 2022-08-23 23:47 EST | News | Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio | N/A | |
| 2022-08-15 10:16 EST | News | Aerie Pharmaceuticals grants 16.9K stock options | N/A | |
| 2022-08-07 19:01 EST | News | Aerie Pharmaceuticals, Inc.'s (AERI) CEO Raj Kannan on Q2 2022 Results - Earnings Call Transcript | N/A | |
About Aerie Pharmaceuticals, Inc (AERI):
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pha read more...rmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
General
- Name Aerie Pharmaceuticals, Inc
- Symbol AERI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 365
- Fiscal Year EndDecember
- IPO Date2013-10-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.aeriepharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 11.09
- Price/Book (Most Recent Quarter) 39.31
- Enterprise Value Revenue 11.15
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.35
- Next Year EPS Estimate -$1.30
- Next Quarter EPS Estimate -$0.65
- Profit Margin -220%
- Operating Margin -187%
- Return on Assets -23%
- Return on Equity -192%
- Revenue 83.14 million
- Earnings Per Share -$5.17
- Revenue Per Share $1.81
- Gross Profit 55.5 million
- Quarterly Earnings Growth 0.1%
Highlights
- Market Capitalization 920.04 million
- EBITDA -199219008
- Analyst Target Price $27.25
- Book Value Per Share $0.51
Share Statistics
- Shares Outstanding 46.92 million
- Shares Float 45.8 million
- % Held by Insiders 211%
- % Held by Institutions 109.26%
- Shares Short 7.32 million
- Shares Short Prior Month 7.02 million
- Short Ratio 9.63
- Short % of Float 21%
- Short % of Shares Outstanding 16%
Technicals
- Beta 0.58
- 52 Week High $21.3
- 52 Week Low $9.01
- 50 Day Moving Average 18
- 200 Day Moving Average 13.82
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Aerie Pharmaceuticals, Inc (AERI) Dividend Calendar:
Aerie Pharmaceuticals, Inc (AERI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Aerie Pharmaceuticals, Inc (AERI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Aerie Pharmaceuticals, Inc (AERI) Chart:
Aerie Pharmaceuticals, Inc (AERI) News:
Below you will find a list of latest news for Aerie Pharmaceuticals, Inc (AERI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Aerie Pharmaceuticals, Inc (AERI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest AERI Trades:
Aerie Pharmaceuticals, Inc (AERI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-10-29 | 8-K (Current report) | |
| 2020-10-28 | 8-K (Current report) | |
| 2020-10-06 | 8-K (Current report) | |
| 2020-09-29 | 8-K (Current report) | |
| 2020-09-24 | 8-K (Current report) | |
| 2020-09-15 | 8-K (Current report) | |
| 2020-09-15 | 8-K (Current report) | |
| 2020-09-09 | 8-K (Current report) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 8-K (Current report) | |
| 2020-08-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-07-27 | 8-K (Current report) | |
| 2020-07-09 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-07-08 | 8-K (Current report) | |
| 2020-06-30 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-30 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-29 | 4 (Statement of changes in beneficial ownership of securities) | |
Aerie Pharmaceuticals, Inc (AERI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aerie Pharmaceuticals, Inc (AERI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 211%
Institutional Ownership: 10926%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-11 | Gerald D. Cagle | Director | Buy | 1,750.00 | 18,300.00 | | ||
| 2020-06-11 | DAVID W GRYSKA | Director | Buy | 1,750.00 | 3,500.00 | | ||
| 2020-06-11 | Julie McHugh | Director | Buy | 1,750.00 | 8,100.00 | | ||
| 2020-06-11 | Richard Croarkin | Director | Buy | 1,750.00 | 8,100.00 | | ||
| 2020-06-11 | Toit Michael du | Director | Buy | 1,750.00 | 8,100.00 | | ||
| 2020-06-11 | BENJAMIN F III MCGRAW | Director | Buy | 1,750.00 | 9,800.00 | | ||
| 2020-05-18 | MURRAY A GOLDBERG | Director | Buy | 28,000.00 | 3.15 | 88,200.00 | 36,050.00 | |
| 2020-05-08 | Gerald D. Cagle | Director | Sell | 5,000.00 | 15.27 | 76,350.00 | 16,550.00 | |
| 2020-02-27 | Foresite Capital Management II, LLC | 10% Share Holder | Sell | 271,767.00 | 17.07 | 4,639,062.69 | 1,229,633.00 | |
| 2020-02-27 | Foresite Capital Management II, LLC | 10% Share Holder | Sell | 302,776.00 | 17.07 | 5,168,386.32 | 1,369,938.00 | |
| 2020-02-27 | Foresite Capital Management II, LLC | 10% Share Holder | Sell | 425,457.00 | 17.07 | 7,262,550.99 | 1,925,020.00 | |
| 2020-02-06 | VICENTE JR ANIDO | Chief Executive Officer | Buy | 28,000.00 | 225,631.00 | | ||
| 2020-02-06 | Casey C. Kopczynski | Chief Scientific Officer | Buy | 10,000.00 | 228,511.00 | | ||
| 2020-02-06 | John LaRocca | General Counsel | Buy | 3,500.00 | 34,958.00 | | ||
| 2020-02-06 | RICHARD J RUBINO | Chief Financial Officer | Buy | 11,750.00 | 351,196.00 | | ||
| 2020-02-06 | THOMAS A MITRO | President and COO | Buy | 14,000.00 | 83,849.00 | | ||
| 2019-12-03 | Casey C. Kopczynski | Chief Scientific Officer | Buy | 117,000.00 | 0.41 | 47,385.00 | 218,511.00 | |
| 2019-11-11 | David Hollander | Chief R&D Officer | Buy | 25,000.00 | 25,000.00 | | ||
| 2019-09-09 | VICENTE JR ANIDO | Chief Executive Officer | Buy | 24,250.00 | 18.93 | 459,052.50 | 195,631.00 | |
| 2019-09-09 | VICENTE JR ANIDO | Chief Executive Officer | Buy | 2,000.00 | 19.95 | 39,900.00 | 197,631.00 | |